Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ting Therapeutics, Inc. currently faces 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners, yet all these individuals are located within 1 distinct art unit. This concentration in a specific art unit suggests that while different examiners are reviewing the applications, they are likely following the same internal supervisory policies and technical standards. The busiest examiner for the portfolio is WELLS, LAUREN QUINLAN, who is responsible for 1 busiest examiner pending action.
This specific pending action is part of the active office actions currently pending for the company. Since the examiners operate within 1 distinct art unit, the prosecution team can focus their research on the specific precedents and tendencies of that specific unit. This unified art unit environment may simplify the coordination of responses across the pending office actions compared to portfolios spread across multiple units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
| RAO, SAVITHA M | 1 | 60.7% | +30.2% |
| CHONG, YONG SOO | 1 | 43.8% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18792993 | Composition and Methods for the Prevention of Aminoglycoside Toxicity | RAO, SAVITHA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18200148 | Methods for the Prevention and Treatment of Hearing Loss | CHONG, YONG SOO | 80d overdue |
| 18888396 | Methods for the Prevention and Treatment of Hearing Loss using Oseltamivir | WELLS, LAUREN QUINLAN | — |
| 18792993 | Composition and Methods for the Prevention of Aminoglycoside Toxicity | RAO, SAVITHA M | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18888396 | Methods for the Prevention and Treatment of Hearing Loss using Oseltamivir | WELLS, LAUREN QUINLAN | — | §102§103DP | Non-Final OA | — | Pending | Sep 18, 2024 |
| 18792993 | Composition and Methods for the Prevention of Aminoglycoside Toxicity | RAO, SAVITHA M | — | §102§103 | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18200148 | Methods for the Prevention and Treatment of Hearing Loss | CHONG, YONG SOO | 1623 | §102 | Final Rejection | 80d overdue | Pending | May 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial